data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+Español
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+Italiano
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+Français
QQQ
––%
DIA
––%
SPY
––%
TLT
––%
GLD
––%
BTC/USD
––%
Contribute
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+Español
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+Italiano
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+Français
Personal Finance
Alts
Best Real Estate Crowdfunding Platforms
REITs Versus Crowdfunding
How to Invest in Artwork
Best Alternative Investments
Best Alternative Investment Platforms
Crypto
Cannabis
News
Earnings
Interviews
Deals
Regulations
Psychedelics
TV
YouTube
Video
Podcasts
Trading School
My Stocks
Tools
Premium
QQQ
––%
DIA
––%
SPY
––%
TLT
––%
GLD
––%
BTC/USD
––%
TCR2 Therapeutics
(NASDAQ:TCRR)
2.885
0.025[0.87%]
Last update: 2:24PM
15 minutes delayed
Day High/Low2.7 - 2.9
52 Week High/Low2.07 - 19.03
Open / Close2.86 / -
Float / Outstanding26.7M / 38.5M
Vol / Avg.138.1K / 496.3K
Mkt Cap111.2M
P/E-
50d Avg. Price2.41
Div / Yield-
Payout Ratio-
EPS-0.76
Total Float26.7M

TCR2 Therapeutics (NASDAQ:TCRR), Quotes and News Summary

TCR2 Therapeutics (NASDAQ: TCRR)

Day High/Low2.7 - 2.9
52 Week High/Low2.07 - 19.03
Open / Close2.86 / -
Float / Outstanding26.7M / 38.5M
Vol / Avg.138.1K / 496.3K
Mkt Cap111.2M
P/E-
50d Avg. Price2.41
Div / Yield-
Payout Ratio-
EPS-0.76
Total Float26.7M
Benzinga - 7 hours ago
Benzinga - May 19, 2022, 6:17AM
Benzinga - May 12, 2022, 6:48AM
Benzinga - Mar 23, 2022, 4:34AM
Benzinga - Mar 22, 2022, 10:47AM
Benzinga - Mar 22, 2022, 6:49AM
Benzinga - Jan 19, 2022, 8:26AM
Benzinga - Jan 13, 2022, 6:22AM
Benzinga - Jan 10, 2022, 6:48AM
Benzinga - Jan 4, 2022, 7:08AM
Benzinga - Nov 10, 2021, 12:34PM
Benzinga - Nov 10, 2021, 6:47AM
Benzinga - Nov 1, 2021, 4:39PM
Benzinga - Oct 25, 2021, 6:50AM
load more
Sector: Health Care.Industry: Biotechnology
TCR2 Therapeutics Inc is a clinical-stage cell therapy company. It is engaged in developing a pipeline of novel T cell therapies for cancer patients suffering from solid tumors by powering the T cell receptor (TCR) with its proprietary, first-in-class TCR Fusion Construct T cells (TRuC-T cells). The company's TRuC-T cells specifically recognize and kill cancer cells by harnessing the entire TCR signaling complex, independent of human leukocyte antigens, which is effective in patients with solid tumors.
Read More

Earnings

see more
Q2 2022Est.ActualSurprise
EPS
(EXPECTED)2022-08-04
REV
Q1 2022Est.ActualSurprise
EPS-0.760
REV0

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target

TCR2 Therapeutics Questions & Answers

Q
How do I buy TCR2 Therapeutics (TCRR) stock?
A

You can purchase shares of TCR2 Therapeutics (NASDAQ: TCRR) through any online brokerage.

View our list of the best stock brokerages.

Q
Who are TCR2 Therapeutics's (TCRR) competitors?
Q
What is the target price for TCR2 Therapeutics (TCRR) stock?
A

The latest price target for TCR2 Therapeutics (NASDAQ: TCRR) was reported by HC Wainwright & Co. on Thursday, May 19, 2022. The analyst firm set a price target for 14.00 expecting TCRR to rise to within 12 months (a possible 385.27% upside). 10 analyst firms have reported ratings in the last year.

Q
Current Stock Price for TCR2 Therapeutics (TCRR)?
A

The stock price for TCR2 Therapeutics (NASDAQ: TCRR) is $2.885 last updated Today at June 27, 2022, 6:24 PM UTC.

Q
Does TCR2 Therapeutics (TCRR) pay a dividend?
A

There are no upcoming dividends for TCR2 Therapeutics.

Q
When is TCR2 Therapeutics (NASDAQ:TCRR) reporting earnings?
A

TCR2 Therapeutics’s Q2 earnings are confirmed for Thursday, August 4, 2022.

Q
Is TCR2 Therapeutics (TCRR) going to split?
A

There is no upcoming split for TCR2 Therapeutics.

Q
What sector and industry does TCR2 Therapeutics (TCRR) operate in?
A

TCR2 Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.